NASDAQ:NMRD Nemaura Medical - NMRD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nemaura Medical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.74 +0.03 (+4.21%) (As of 03/22/2023 01:55 PM ET) Add Compare Share Share Today's Range$0.70▼$0.7450-Day Range$0.71▼$2.8652-Week Range$0.70▼$4.58Volume32,936 shsAverage Volume184,826 shsMarket Capitalization$21.38 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Nemaura Medical MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside812.9% Upside$6.50 Price TargetShort InterestHealthy0.26% of Float Sold ShortDividend StrengthN/ASustainability-0.97Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.56) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.57 out of 5 starsMedical Sector104th out of 983 stocksSurgical & Medical Instruments Industry11th out of 100 stocks 3.5 Analyst's Opinion Consensus RatingNemaura Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.50, Nemaura Medical has a forecasted upside of 812.9% from its current price of $0.71.Amount of Analyst CoverageNemaura Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.26% of the float of Nemaura Medical has been sold short.Short Interest Ratio / Days to CoverNemaura Medical has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nemaura Medical has recently decreased by 71.72%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNemaura Medical does not currently pay a dividend.Dividend GrowthNemaura Medical does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNemaura Medical has received a 69.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Continuous glucose monitoring systems", "Continuous substance abuse monitoring systems", and "Continuous alcohol monitoring systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Nemaura Medical is -0.97. Previous Next 2.8 News and Social Media Coverage News SentimentNemaura Medical has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nemaura Medical this week, compared to 0 articles on an average week.Search InterestOnly 10 people have searched for NMRD on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Nemaura Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nemaura Medical insiders have not sold or bought any company stock.Percentage Held by Insiders49.80% of the stock of Nemaura Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.41% of the stock of Nemaura Medical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nemaura Medical are expected to grow in the coming year, from ($0.56) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nemaura Medical is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nemaura Medical is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNemaura Medical has a P/B Ratio of 35.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nemaura Medical (NASDAQ:NMRD) StockNemaura Medical, Inc. operates as a holding company. The firm engages in the provision of medical device research. It manufactures and commercializes glucose monitoring system, named sugarBEAT. The sugarBEAT consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals with the use of a mobile app. The company was founded by Dewan Fazlul Hoque Chowdhury on December 24, 2013 and is headquartered in New York, NY.Read More Receive NMRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nemaura Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address NMRD Stock News HeadlinesMarch 21, 2023 | finance.yahoo.comNemaura Medical to Participate in Fireside Chat Hosted by EF HuttonMarch 15, 2023 | finance.yahoo.comNemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License AgreementMarch 22, 2023 | Investing Daily (Ad)This Trade Strategy Outpaces Almost AnythingDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. March 9, 2023 | finance.yahoo.comNemaura Medical Announces Receipt of Notice from NasdaqFebruary 24, 2023 | finanznachrichten.deNemaura Medical, Inc: Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business UpdateFebruary 24, 2023 | finance.yahoo.comNemaura Medical, Inc. (NMRD) Reports Q3 Loss, Lags Revenue EstimatesFebruary 24, 2023 | finance.yahoo.comNemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business UpdateFebruary 16, 2023 | finance.yahoo.comNemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual ConferenceMarch 22, 2023 | Investing Daily (Ad)This Trade Strategy Outpaces Almost AnythingDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. January 31, 2023 | finance.yahoo.comNemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private PlacementJanuary 27, 2023 | finance.yahoo.comNemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private PlacementJanuary 26, 2023 | marketwatch.comNemaura Medical Shares Rise 19% After New Purchase OrderJanuary 26, 2023 | finance.yahoo.comNemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleetJanuary 24, 2023 | finance.yahoo.comNemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of ParticipantsJanuary 11, 2023 | finance.yahoo.comNemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual ConferenceJanuary 7, 2023 | forbes.comNemaura MedicalJanuary 4, 2023 | finance.yahoo.comNemaura Medical Inc. (NMRD)December 1, 2022 | finance.yahoo.comNemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022November 29, 2022 | finance.yahoo.comNemaura Commences Pilot Program of Miboko with the NHS in the United KingdomNovember 15, 2022 | finance.yahoo.comNemaura Medical, Inc. (NMRD) Reports Q2 Loss, Misses Revenue EstimatesNovember 15, 2022 | finance.yahoo.comNemaura Medical Reports Fiscal Second Quarter 2023 Results and Provides Business UpdateNovember 11, 2022 | finance.yahoo.comNemaura Medical to Present at the Bernstein 2ND Annual CGM Disruptors ConferenceNovember 4, 2022 | finance.yahoo.comNemaura Medical, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)October 12, 2022 | finance.yahoo.comNemaura Receives Provisional Purchase Order from Middle East Licensee TPMENAOctober 6, 2022 | marketwatch.comInvestorNewsBreaks - Nemaura Medical Inc. (NASDAQ: NMRD) Announces Participation at Upcoming MicroCap Rodeo Windy City RoundupOctober 4, 2022 | finance.yahoo.comNemaura Medical to Present at the MicroCap Rodeo Windy City Roundup 2022 ConferenceSeptember 30, 2022 | finanznachrichten.deFinancialBuzz.com: Wearable Medical Devices Revolutionize How Patient Data Can be TrackedSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NMRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nemaura Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address NMRD Company Calendar Last Earnings11/15/2021Today3/22/2023Fiscal Year End3/31/2023Next Earnings (Estimated)6/29/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NMRD CUSIPN/A CIK1602078 Webnemauramedical.com Phone(646) 416-8000FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.50 High Stock Price Forecast$7.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+812.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,890,000.00 Net MarginsN/A Pretax Margin-3,382.37% Return on Equity-2,921.93% Return on Assets-75.78% Debt Debt-to-Equity RatioN/A Current Ratio0.83 Quick Ratio0.65 Sales & Book Value Annual Sales$500,000.00 Price / Sales41.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book35.60Miscellaneous Outstanding Shares28,900,000Free Float14,507,000Market Cap$20.58 million OptionableOptionable Beta-0.02 Key ExecutivesDewan Fazlul Hoque ChowdhuryChairman, President, CEO, CFO & CAOArash GhadarChief Operating OfficerRichard ToonManager-Technical & Business DevelopmentBashir TimolDirector & Chief Business OfficerJay L. WarnerHead-US Commercial OperationsKey CompetitorsAcutus MedicalNASDAQ:AFIBSeaStar MedicalNASDAQ:ICUNeuroOne Medical TechnologiesNASDAQ:NMTCTenon MedicalNASDAQ:TNONTitan MedicalNASDAQ:TMDIView All Competitors NMRD Stock - Frequently Asked Questions Should I buy or sell Nemaura Medical stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nemaura Medical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NMRD shares. View NMRD analyst ratings or view top-rated stocks. What is Nemaura Medical's stock price forecast for 2023? 2 Wall Street analysts have issued 12-month target prices for Nemaura Medical's stock. Their NMRD share price forecasts range from $6.00 to $7.00. On average, they predict the company's share price to reach $6.50 in the next year. This suggests a possible upside of 812.9% from the stock's current price. View analysts price targets for NMRD or view top-rated stocks among Wall Street analysts. How have NMRD shares performed in 2023? Nemaura Medical's stock was trading at $1.7171 at the beginning of the year. Since then, NMRD shares have decreased by 58.5% and is now trading at $0.7120. View the best growth stocks for 2023 here. Are investors shorting Nemaura Medical? Nemaura Medical saw a decrease in short interest in February. As of February 28th, there was short interest totaling 37,700 shares, a decrease of 71.7% from the February 13th total of 133,300 shares. Based on an average trading volume of 153,300 shares, the short-interest ratio is currently 0.2 days. Approximately 0.3% of the shares of the company are short sold. View Nemaura Medical's Short Interest. When is Nemaura Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 29th 2023. View our NMRD earnings forecast. How were Nemaura Medical's earnings last quarter? Nemaura Medical Inc. (NASDAQ:NMRD) released its earnings results on Monday, November, 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.04. What is Nemaura Medical's stock symbol? Nemaura Medical trades on the NASDAQ under the ticker symbol "NMRD." Who are Nemaura Medical's major shareholders? Nemaura Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Nemaura Medical? Shares of NMRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nemaura Medical's stock price today? One share of NMRD stock can currently be purchased for approximately $0.71. How much money does Nemaura Medical make? Nemaura Medical (NASDAQ:NMRD) has a market capitalization of $20.58 million and generates $500,000.00 in revenue each year. The company earns $-13,890,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. How can I contact Nemaura Medical? Nemaura Medical's mailing address is 57 WEST 57TH STREET, MANHATTAN NY, 10019. The official website for the company is nemauramedical.com. The company can be reached via phone at (646) 416-8000 or via email at brets@coreir.com. This page (NASDAQ:NMRD) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.